EPS Bio Technology Corp

The company's capital structure shows a debt-to-equity ratio of 0.5, indicating a moderate reliance on debt financing. With cash and equivalents of TWD 123,078,000 and total liabilities of TWD 252,141,000, the firm maintains a current ratio of 2.3, suggesting reasonable short-term liquidity. However, the negative free cash flow of TWD -32,397,000 and capital expenditure of TWD -23,969,000 highlight ongoing cash outflows that could pressure liquidity in the near term. Profitability metrics are weak, with a net loss of TWD -7,866,000 and an operating loss of TWD -9,097,000. Return on equity is -2.8%, and return on assets is -1.48%, both significantly below the industry median for medical equipment and supplies. Gross profit of TWD 87,043,000 represents 17.4% of revenue, which is in line with the industry but insufficient to offset operating costs. The company's revenue is concentrated in overseas markets, particularly Europe, North America, and other Asian regions. No specific segment breakdown is available, but the geographic exposure suggests vulnerability to regulatory changes or trade disruptions in these regions. The lack of disclosed regional revenue percentages limits the ability to assess concentration risk precisely. Growth trajectory appears mixed. While the company reported a revenue of TWD 499,704,000 in the latest period, the operating and net losses suggest operational inefficiencies. The outlook for the current fiscal year is uncertain, with no clear indication of improvement in profitability or cash flow generation. The absence of analyst estimates for the next fiscal year further complicates growth projections. Risk factors include a negative net cash position after subtracting total debt, which raises liquidity concerns. The company's liquidity risk is rated as medium, and while dilution risk is currently low, the negative free cash flow and capital expenditure could necessitate future financing, potentially leading to share dilution. No recent filings or transcripts have been provided to assess management's response to these challenges. Recent events and disclosures are limited in the provided data. No specific filings, earnings calls, or transcripts are available to assess management's strategy or operational updates. The absence of recent financial or strategic developments makes it difficult to evaluate the company's response to market conditions or competitive pressures.